Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. We performed a multicenter retrospective real-world analysis of patients with mCRC receiving t...
Gespeichert in:
| Veröffentlicht in: | Clinical colorectal cancer 2021-12, Vol.20 (4), p.342-349 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 349 |
|---|---|
| container_issue | 4 |
| container_start_page | 342 |
| container_title | Clinical colorectal cancer |
| container_volume | 20 |
| creator | Stavraka, Chara Pouptsis, Athanasios Synowiec, Alicja Angelis, Vasileios Satterthwaite, Liyana Khan, Sam Chauhan, Meera Holden, Chloe Young, Sally Karampera, Christina Martinou, Maria Mills-Baldock, Tina Baxter, Mark Barry, Ainsley Eccles, Bryony Iveson, Timothy Shiu, Kai-Keen Hill, Mark Abdel-Raouf, Sherif Graham, Janet Shirley Thomas, Anne Ross, Paul J. |
| description | The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.
We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom.
A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR |
| doi_str_mv | 10.1016/j.clcc.2021.09.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2586456771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1533002821000955</els_id><sourcerecordid>2586456771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-93e11edf6407fa1504ec85477ded481c71700ba73729050f81a978095454de333</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRCIfsAf4IB85NCk49iJE8RltWoLohUItmfLtSfIK6-92E7R_g7-MI62cERzmBnNmzea96rqDYWGAu0vt412WjcttLSBsQEYn1WndGRDDb3gz0vdMVYDtMNJdZbStlQ9o_RldcJ4P5boTqvfm2gnN0drrMfLjd3bqLR1xHpyh1mlrLLVZB1ciKizcmStvMb4nqzI_WdyN7syRp8xkm-oXP0rRGfIyit3SDaR4MnVNFmt9OGCfFcT5pK_RjRWZ_uIRHlT2vDDh7ScuVY6h5heVS8m5RK-fsrn1f311Wb9sb79cvNpvbqtNQfI9ciQUjRTz0FMinbAUQ8dF8Kg4QPVggqAByWYaEfoYBqoGsUAY8c7bpAxdl69O_LuY_g5Y8pyZ5NG55THMCfZdkPPu14IWqDtEapjSCniJPfR7lQ8SApyMUNu5WKGXMyQMMpiRll6-8Q_P-zQ_Fv5q34BfDgCsHz5aDHKpC0WfY1d1JYm2P_x_wEUjZt0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586456771</pqid></control><display><type>article</type><title>Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Stavraka, Chara ; Pouptsis, Athanasios ; Synowiec, Alicja ; Angelis, Vasileios ; Satterthwaite, Liyana ; Khan, Sam ; Chauhan, Meera ; Holden, Chloe ; Young, Sally ; Karampera, Christina ; Martinou, Maria ; Mills-Baldock, Tina ; Baxter, Mark ; Barry, Ainsley ; Eccles, Bryony ; Iveson, Timothy ; Shiu, Kai-Keen ; Hill, Mark ; Abdel-Raouf, Sherif ; Graham, Janet Shirley ; Thomas, Anne ; Ross, Paul J.</creator><creatorcontrib>Stavraka, Chara ; Pouptsis, Athanasios ; Synowiec, Alicja ; Angelis, Vasileios ; Satterthwaite, Liyana ; Khan, Sam ; Chauhan, Meera ; Holden, Chloe ; Young, Sally ; Karampera, Christina ; Martinou, Maria ; Mills-Baldock, Tina ; Baxter, Mark ; Barry, Ainsley ; Eccles, Bryony ; Iveson, Timothy ; Shiu, Kai-Keen ; Hill, Mark ; Abdel-Raouf, Sherif ; Graham, Janet Shirley ; Thomas, Anne ; Ross, Paul J.</creatorcontrib><description>The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.
We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom.
A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR <5 and CEA <200 had favorable prognostic (HR: 0.52 and 0.39, P≤ .001) and predictive value (OR: 4.1 and 6.7, P< .05). Development of grade 3 neutropenia predicted treatment response (OR: 0.32, P< .001). Following treatment with trifluridine/tipiracil 41% were referred for phase I trial or rechallenged with chemotherapy.
Trifluridine/tipiracil is well tolerated in refractory mCRC patients with comparable efficacy and toxicity profile to that of the phase III RECOURSE. Pretreatment NLR and CEA could serve as potential markers for patient selection, while treatment-induced grade 3 neutropenia predicted response. Prospective validation is needed.
This multicenter retrospective study assessed the safety and efficacy of trifluridine/tipiracil in the real-world setting in patients with chemotherapy refractory metastatic colorectal cancer (mCRC), while identifying predictive and prognostic clinicopathological factors. Our findings suggest that real-world safety and efficacy of trifluridine/tipiracil are in keeping with the pivotal clinical trial outcomes. Pretreatment neutrophil to lymphocyte ratio (NLR) and carcinoembryonic antigen (CEA) were prognostic, while treatment-induced grade 3 neutropenia was predictive for response.</description><identifier>ISSN: 1533-0028</identifier><identifier>EISSN: 1938-0674</identifier><identifier>DOI: 10.1016/j.clcc.2021.09.009</identifier><identifier>PMID: 34696965</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Colorectal Neoplasms - drug therapy ; Humans ; Lonsurf ; Neutropenia ; Prognosis ; Pyrrolidines ; Real-world evidence ; Retrospective Studies ; TAS-102 ; Thymine ; Treatment outcomes ; Trifluridine - adverse effects ; Uracil - adverse effects</subject><ispartof>Clinical colorectal cancer, 2021-12, Vol.20 (4), p.342-349</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-93e11edf6407fa1504ec85477ded481c71700ba73729050f81a978095454de333</citedby><cites>FETCH-LOGICAL-c400t-93e11edf6407fa1504ec85477ded481c71700ba73729050f81a978095454de333</cites><orcidid>0000-0001-7623-299X ; 0000-0002-8787-0353 ; 0000-0002-2390-1886</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clcc.2021.09.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34696965$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stavraka, Chara</creatorcontrib><creatorcontrib>Pouptsis, Athanasios</creatorcontrib><creatorcontrib>Synowiec, Alicja</creatorcontrib><creatorcontrib>Angelis, Vasileios</creatorcontrib><creatorcontrib>Satterthwaite, Liyana</creatorcontrib><creatorcontrib>Khan, Sam</creatorcontrib><creatorcontrib>Chauhan, Meera</creatorcontrib><creatorcontrib>Holden, Chloe</creatorcontrib><creatorcontrib>Young, Sally</creatorcontrib><creatorcontrib>Karampera, Christina</creatorcontrib><creatorcontrib>Martinou, Maria</creatorcontrib><creatorcontrib>Mills-Baldock, Tina</creatorcontrib><creatorcontrib>Baxter, Mark</creatorcontrib><creatorcontrib>Barry, Ainsley</creatorcontrib><creatorcontrib>Eccles, Bryony</creatorcontrib><creatorcontrib>Iveson, Timothy</creatorcontrib><creatorcontrib>Shiu, Kai-Keen</creatorcontrib><creatorcontrib>Hill, Mark</creatorcontrib><creatorcontrib>Abdel-Raouf, Sherif</creatorcontrib><creatorcontrib>Graham, Janet Shirley</creatorcontrib><creatorcontrib>Thomas, Anne</creatorcontrib><creatorcontrib>Ross, Paul J.</creatorcontrib><title>Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors</title><title>Clinical colorectal cancer</title><addtitle>Clin Colorectal Cancer</addtitle><description>The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.
We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom.
A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR <5 and CEA <200 had favorable prognostic (HR: 0.52 and 0.39, P≤ .001) and predictive value (OR: 4.1 and 6.7, P< .05). Development of grade 3 neutropenia predicted treatment response (OR: 0.32, P< .001). Following treatment with trifluridine/tipiracil 41% were referred for phase I trial or rechallenged with chemotherapy.
Trifluridine/tipiracil is well tolerated in refractory mCRC patients with comparable efficacy and toxicity profile to that of the phase III RECOURSE. Pretreatment NLR and CEA could serve as potential markers for patient selection, while treatment-induced grade 3 neutropenia predicted response. Prospective validation is needed.
This multicenter retrospective study assessed the safety and efficacy of trifluridine/tipiracil in the real-world setting in patients with chemotherapy refractory metastatic colorectal cancer (mCRC), while identifying predictive and prognostic clinicopathological factors. Our findings suggest that real-world safety and efficacy of trifluridine/tipiracil are in keeping with the pivotal clinical trial outcomes. Pretreatment neutrophil to lymphocyte ratio (NLR) and carcinoembryonic antigen (CEA) were prognostic, while treatment-induced grade 3 neutropenia was predictive for response.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Lonsurf</subject><subject>Neutropenia</subject><subject>Prognosis</subject><subject>Pyrrolidines</subject><subject>Real-world evidence</subject><subject>Retrospective Studies</subject><subject>TAS-102</subject><subject>Thymine</subject><subject>Treatment outcomes</subject><subject>Trifluridine - adverse effects</subject><subject>Uracil - adverse effects</subject><issn>1533-0028</issn><issn>1938-0674</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQjRCIfsAf4IB85NCk49iJE8RltWoLohUItmfLtSfIK6-92E7R_g7-MI62cERzmBnNmzea96rqDYWGAu0vt412WjcttLSBsQEYn1WndGRDDb3gz0vdMVYDtMNJdZbStlQ9o_RldcJ4P5boTqvfm2gnN0drrMfLjd3bqLR1xHpyh1mlrLLVZB1ciKizcmStvMb4nqzI_WdyN7syRp8xkm-oXP0rRGfIyit3SDaR4MnVNFmt9OGCfFcT5pK_RjRWZ_uIRHlT2vDDh7ScuVY6h5heVS8m5RK-fsrn1f311Wb9sb79cvNpvbqtNQfI9ciQUjRTz0FMinbAUQ8dF8Kg4QPVggqAByWYaEfoYBqoGsUAY8c7bpAxdl69O_LuY_g5Y8pyZ5NG55THMCfZdkPPu14IWqDtEapjSCniJPfR7lQ8SApyMUNu5WKGXMyQMMpiRll6-8Q_P-zQ_Fv5q34BfDgCsHz5aDHKpC0WfY1d1JYm2P_x_wEUjZt0</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Stavraka, Chara</creator><creator>Pouptsis, Athanasios</creator><creator>Synowiec, Alicja</creator><creator>Angelis, Vasileios</creator><creator>Satterthwaite, Liyana</creator><creator>Khan, Sam</creator><creator>Chauhan, Meera</creator><creator>Holden, Chloe</creator><creator>Young, Sally</creator><creator>Karampera, Christina</creator><creator>Martinou, Maria</creator><creator>Mills-Baldock, Tina</creator><creator>Baxter, Mark</creator><creator>Barry, Ainsley</creator><creator>Eccles, Bryony</creator><creator>Iveson, Timothy</creator><creator>Shiu, Kai-Keen</creator><creator>Hill, Mark</creator><creator>Abdel-Raouf, Sherif</creator><creator>Graham, Janet Shirley</creator><creator>Thomas, Anne</creator><creator>Ross, Paul J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7623-299X</orcidid><orcidid>https://orcid.org/0000-0002-8787-0353</orcidid><orcidid>https://orcid.org/0000-0002-2390-1886</orcidid></search><sort><creationdate>202112</creationdate><title>Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors</title><author>Stavraka, Chara ; Pouptsis, Athanasios ; Synowiec, Alicja ; Angelis, Vasileios ; Satterthwaite, Liyana ; Khan, Sam ; Chauhan, Meera ; Holden, Chloe ; Young, Sally ; Karampera, Christina ; Martinou, Maria ; Mills-Baldock, Tina ; Baxter, Mark ; Barry, Ainsley ; Eccles, Bryony ; Iveson, Timothy ; Shiu, Kai-Keen ; Hill, Mark ; Abdel-Raouf, Sherif ; Graham, Janet Shirley ; Thomas, Anne ; Ross, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-93e11edf6407fa1504ec85477ded481c71700ba73729050f81a978095454de333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Lonsurf</topic><topic>Neutropenia</topic><topic>Prognosis</topic><topic>Pyrrolidines</topic><topic>Real-world evidence</topic><topic>Retrospective Studies</topic><topic>TAS-102</topic><topic>Thymine</topic><topic>Treatment outcomes</topic><topic>Trifluridine - adverse effects</topic><topic>Uracil - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stavraka, Chara</creatorcontrib><creatorcontrib>Pouptsis, Athanasios</creatorcontrib><creatorcontrib>Synowiec, Alicja</creatorcontrib><creatorcontrib>Angelis, Vasileios</creatorcontrib><creatorcontrib>Satterthwaite, Liyana</creatorcontrib><creatorcontrib>Khan, Sam</creatorcontrib><creatorcontrib>Chauhan, Meera</creatorcontrib><creatorcontrib>Holden, Chloe</creatorcontrib><creatorcontrib>Young, Sally</creatorcontrib><creatorcontrib>Karampera, Christina</creatorcontrib><creatorcontrib>Martinou, Maria</creatorcontrib><creatorcontrib>Mills-Baldock, Tina</creatorcontrib><creatorcontrib>Baxter, Mark</creatorcontrib><creatorcontrib>Barry, Ainsley</creatorcontrib><creatorcontrib>Eccles, Bryony</creatorcontrib><creatorcontrib>Iveson, Timothy</creatorcontrib><creatorcontrib>Shiu, Kai-Keen</creatorcontrib><creatorcontrib>Hill, Mark</creatorcontrib><creatorcontrib>Abdel-Raouf, Sherif</creatorcontrib><creatorcontrib>Graham, Janet Shirley</creatorcontrib><creatorcontrib>Thomas, Anne</creatorcontrib><creatorcontrib>Ross, Paul J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical colorectal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stavraka, Chara</au><au>Pouptsis, Athanasios</au><au>Synowiec, Alicja</au><au>Angelis, Vasileios</au><au>Satterthwaite, Liyana</au><au>Khan, Sam</au><au>Chauhan, Meera</au><au>Holden, Chloe</au><au>Young, Sally</au><au>Karampera, Christina</au><au>Martinou, Maria</au><au>Mills-Baldock, Tina</au><au>Baxter, Mark</au><au>Barry, Ainsley</au><au>Eccles, Bryony</au><au>Iveson, Timothy</au><au>Shiu, Kai-Keen</au><au>Hill, Mark</au><au>Abdel-Raouf, Sherif</au><au>Graham, Janet Shirley</au><au>Thomas, Anne</au><au>Ross, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors</atitle><jtitle>Clinical colorectal cancer</jtitle><addtitle>Clin Colorectal Cancer</addtitle><date>2021-12</date><risdate>2021</risdate><volume>20</volume><issue>4</issue><spage>342</spage><epage>349</epage><pages>342-349</pages><issn>1533-0028</issn><eissn>1938-0674</eissn><abstract>The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.
We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom.
A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR <5 and CEA <200 had favorable prognostic (HR: 0.52 and 0.39, P≤ .001) and predictive value (OR: 4.1 and 6.7, P< .05). Development of grade 3 neutropenia predicted treatment response (OR: 0.32, P< .001). Following treatment with trifluridine/tipiracil 41% were referred for phase I trial or rechallenged with chemotherapy.
Trifluridine/tipiracil is well tolerated in refractory mCRC patients with comparable efficacy and toxicity profile to that of the phase III RECOURSE. Pretreatment NLR and CEA could serve as potential markers for patient selection, while treatment-induced grade 3 neutropenia predicted response. Prospective validation is needed.
This multicenter retrospective study assessed the safety and efficacy of trifluridine/tipiracil in the real-world setting in patients with chemotherapy refractory metastatic colorectal cancer (mCRC), while identifying predictive and prognostic clinicopathological factors. Our findings suggest that real-world safety and efficacy of trifluridine/tipiracil are in keeping with the pivotal clinical trial outcomes. Pretreatment neutrophil to lymphocyte ratio (NLR) and carcinoembryonic antigen (CEA) were prognostic, while treatment-induced grade 3 neutropenia was predictive for response.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34696965</pmid><doi>10.1016/j.clcc.2021.09.009</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7623-299X</orcidid><orcidid>https://orcid.org/0000-0002-8787-0353</orcidid><orcidid>https://orcid.org/0000-0002-2390-1886</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1533-0028 |
| ispartof | Clinical colorectal cancer, 2021-12, Vol.20 (4), p.342-349 |
| issn | 1533-0028 1938-0674 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2586456771 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Colorectal Neoplasms - drug therapy Humans Lonsurf Neutropenia Prognosis Pyrrolidines Real-world evidence Retrospective Studies TAS-102 Thymine Treatment outcomes Trifluridine - adverse effects Uracil - adverse effects |
| title | Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A20%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trifluridine/Tipiracil%20in%20Metastatic%20Colorectal%20Cancer:%20A%20UK%20Multicenter%20Real-world%20Analysis%20on%20Efficacy,%20Safety,%20Predictive%20and%20Prognostic%20Factors&rft.jtitle=Clinical%20colorectal%20cancer&rft.au=Stavraka,%20Chara&rft.date=2021-12&rft.volume=20&rft.issue=4&rft.spage=342&rft.epage=349&rft.pages=342-349&rft.issn=1533-0028&rft.eissn=1938-0674&rft_id=info:doi/10.1016/j.clcc.2021.09.009&rft_dat=%3Cproquest_cross%3E2586456771%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586456771&rft_id=info:pmid/34696965&rft_els_id=S1533002821000955&rfr_iscdi=true |